Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation

Jason D. Roberts, Thomas Dewland, David V. Glidden, Thomas J. Hoffmann, Dan E. Arking, Lin Y. Chen, Bruce M. Psaty, Jeffrey E. Olgin, Alvaro Alonso, Susan R. Heckbert, Gregory M. Marcus

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. Methods We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalAmerican Heart Journal
Volume175
DOIs
Publication statusPublished - May 1 2016
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this